Technical Advantage

Technological Advantages

Technical Advantage

Beijing Tiantan Hospital Affiliated to Capital Medical University


Beijing Tiantan Hospital is a comprehensive, Grade-III Class-A teaching hospital led by its neurosurgery department—and it ranks among the world’s three leading centers for neurosurgical research. The National Clinical Research Center for Neurological Diseases is headquartered at this hospital, making it the largest clinical research platform in China dedicated to neurological disorders.

In 2018, Jiuzhitang Maker signed the "Joint Construction Agreement for a Clinical Stem Cell Research Base" with Beijing Tiantan Hospital. The two parties will continue to advance preclinical research on stem cells. On January 12, 2021, China’s first Phase I/IIa clinical trial (ASSIST) using imported stem cells to treat ischemic stroke was officially launched. This marks the first clinical trial of stem cell therapy for cerebrovascular diseases conducted under the new version of the "Good Clinical Practice Guidelines for Drug Clinical Trials," since the state began regulating stem cells as pharmaceuticals. The trial is highly significant, not only for paving the way toward the clinical application of stem cells in cerebrovascular disease treatment but also for driving broader changes in the overall management system governing stem cell applications.